3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
9
Tumor-Agnostic
2
Thoracic
2
Gynecologic
2
Genitourinary
2
Head & Neck
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Trastuzumab
696
Paclitaxel
679
Cyclophosphamide
634
Docetaxel
554
Capecitabine
468
Letrozole
407
Carboplatin
393
Fulvestrant
379
Doxorubicin
330
Tamoxifen
288
pembrolizumab
272
Anastrozole
252
Epirubicin
249
exemestane
238
pertuzumab
229
Bevacizumab
214
Radiotherapy
213
Gemcitabine
211
Vinorelbine
188
palbociclib
183
Lapatinib
175
130-nm albumin-bound paclitaxel
168
Albumin-Bound Paclitaxel
156
Exercise
147
Magnetic Resonance Spectroscopy
145
eribulin
144
Taxes
134
Fluorouracil
131
Everolimus
118
Cisplatin
118
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
bemarituzumab
×
Breast
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled